Careful consideration needs to be given to the combination of STING agonists with VEGF blockers, as this may inhibit T‐cell infiltration by suppressing the proliferation of endothelial cells within the tumor, leading to the progression of certain cancer types. Here, STING1 is linked to neoplasm.